[Cross reactivity between ACE inhibitors and angiotensin receptor blockers].
Rosenborg
Staffan
S
D000799:Angioedema / Q000139:chemically induced*; D047228:Angiotensin II Type 1 Receptor Blockers / Q000009:adverse effects*; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000009:adverse effects*; D000959:Antihypertensive Agents / Q000009:adverse effects*; D001562:Benzimidazoles / Q000009:adverse effects; D001713:Biphenyl Compounds / Q000009:adverse effects; D004656:Enalapril / Q000009:adverse effects; D019317:Evidence-Based Medicine; D006801:Humans; D012307:Risk Factors; D013777:Tetrazoles / Q000009:adverse effects
D047228:Angiotensin II Type 1 Receptor Blockers; D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents; D001562:Benzimidazoles; D001713:Biphenyl Compounds; D013777:Tetrazoles; D004656:Enalapril; C077793:candesartan cilexetil